RxDoctor Payments Data

Catherine Vanderloos

Obstetrics & Gynecology · Shreveport, LANPI 1588840888

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $34,007 of the $54,809 with a category attached, or 62.0%. 21 manufacturers reported payments, led by Duchesnay USA Incorporated at 44.4% of the total. Reporting peaked in 2019 at $38,705 and has fallen 99.7% since, to $106 in 2025. Among obstetrics & gynecology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$54,809in general payments, 2019–2025

Across 271 payments — averaging $202.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Duchesnay USA Incorporated$24K
  • Coopersurgical, Inc.$14K
  • Lupin Inc.$14K
  • AbbVie$450
  • Currax Pharmaceuticals LLC$354
  • Evofem Biosciences, Inc.$324
  • plus $1K from 15 others

What the payments were for

  • Consulting fees$10,58319%
  • Speaking & faculty fees$34,00762%
  • Travel & lodging$3,1766%
  • Food & beverage$6,89613%
  • Education$1470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,809 in reported general payments places this provider in the 95th percentile of 608 obstetrics & gynecology providers in Louisiana.

See all obstetrics & gynecology providers in Louisiana

Medicare billing

Part B allowed, 2024
$38,737
Medicare patients
260
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated22$9,005
Estradiol249$4,734
Clobetasol Propionate50$2,027
Clindamycin Phosphate32$1,859
Estradiol (Twice Weekly)Estradiol23$1,676
Estradiol (Once Weekly)Estradiol23$1,272
ProgesteroneProgesterone, Micronized47$1,138
Acyclovir70$948
Terconazole24$724
Nystatin39$467
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst25$332
Fluconazole71$295
Oxybutynin Chloride ErOxybutynin Chloride26$276
Trazodone Hcl47$263
Alendronate Sodium25$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$186$9,00522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 608 obstetrics & gynecology providers in Louisiana.

Other obstetrics & gynecology in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →